Topical treatment of cutaneous Kaposi sarcoma with imiquimod 5% in renal-transplant recipients: a clinicopathological observation.

@article{Vavricka2012TopicalTO,
  title={Topical treatment of cutaneous Kaposi sarcoma with imiquimod 5% in renal-transplant recipients: a clinicopathological observation.},
  author={Bettina M Prinz Vavricka and G{\"u}nther F L Hofbauer and Reinhard Dummer and Lars Einar French and W. Kempf},
  journal={Clinical and experimental dermatology},
  year={2012},
  volume={37 6},
  pages={
          620-5
        }
}
Kaposi sarcoma (KS) is a vascular neoplasm pathogenetically linked to human herpesvirus 8. Transplant recipients, in particular renal-transplant recipients (RTRs) are at higher risk for post-transplant (P)-KS which affects 0.2-11% of RTRs. The course of P-KS is influenced by the post-transplantation immunosuppressive treatment. Reduction of immunosuppressive drugs can result in tumour regression, and is the treatment of choice for P-KS, but is associated with the risk for transplant rejection… CONTINUE READING
BETA

From This Paper

Topics from this paper.

Similar Papers

Loading similar papers…